Warner-lambert Company

Pfizer Corporation

Ortho Pharmaceutical Corporation

David Juergen Wustrow

Lawrence D Wise

Andrew John Thorpe

Justin Stephen Bryans

David Christopher Horwell

Thomas R Belliotti

Juan C Jaen

Suzanne Ross Kesten

Po-wai Yuen

Jacob Bradley Schwarz

Stephen J Johnson

Sarah J Smith

Clare Octavia Kneen

David James Dooley

Donna M Reynolds

David G Nickell

Charles F Schwender

Charles Price Taylor, Jr

William J Smith, Iii

Bradley W Caprathe

Lain-Yen Hu

Thomas Capiris

Jonathan L Wright

Augustine Tobi Osuma

Denis Schrier

Huangshu Lei

Dennis M Downing

Nancy Sue Barta

Howard Glenn Welgus

Ihoezo Victor Ekhato

Keith Demarest

Donald E Butler

John H Dodd

Clifton J Blankley

Sheryl Jeanne Hays

Todd Robert Ryder

Tung V Le

Jean-Marie Receveur

Christopher Peter Wayman

Robert Michael Schelkun

Norman Lloyd Colbry

Thomas A Pugsley

Sean Donevan

Zhijian Zhu

Pieter Hadewijn Van Der Graaf

Jodette Gailey

William John Smith, Iii

Jeffrey David Scholten

Raymond Hudack, Jr

Kristin Knapp Lin

Rong Ling

Thomas Richard Belliotti

Po-Wai Yuen

Lawrence David Wise

This invention relates to certain &#x3b2;-amino acids that bind to the alpha-2-delta (&#x3b1;2&#x3b4;) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.

Amino acids with affinity for the &#x3b1;2&#x3b4;-protein

This invention relates to prodrugs of certain amino acids that bind to the alpha-2-delta (&#x3b1;2&#x3b4;) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.

Prodrugs of amino acids with affinity for the &#x3b1;2&#x3b4;-protein

Use of an alpha-2-delta ligand, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of premature ejaculation.

Method of treatment for sexual dysfunction

This invention relates to a method of treating a disorder selected from OCD, agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, PTSD, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia by administering a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein: Ris hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl; and Ris straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The invention also relates to a method of treating the above disorders by administering the compound (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid.

Alpha 2 delta ligands for post-traumatic stress disorder

This invention relates to novel tetrazole and oxadiazalone &#x3b2;-amino acids derivatives of the formula wherein G is wherein Rthrough Rare defined as in the specification, pharmaceutical compositions containing them and their use for the treatment of various central nervous system and other disorders. The cyclopropyl &#x3b2;-amino acids derivatives of this invention exhibit activity as alpha2delta ligands (&#x3b1;2&#x3b4; ligands). Such compounds have affinity for the &#x3b1;2&#x3b4; subunit of a calcium channel.

Tetrazole and oxadiazolone substituted &#x3b2;-amino acid derivatives

The invention relates to a method of preventing or treating cartilage damage by administering a GABA analog such as, for example, a compound of Formula and pharmaceutically acceptable salts thereof, wherein Ris hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

Method of treating noninflammatory cartilage damage

This invention relates to a method of treating a disorder selected from OCD, agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, PTSD, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia by administering a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein:

Alpha2delta ligands for fibromyalgia and other disorders

The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formula and pharmaceutically acceptable salts thereof, wherein Ris hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

Method of treating tinnitus

The invention is a novel series of cyclic amino acids which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as well as methods of preparing the compounds and novel intermediates useful in the preparation of the final compounds are included.

Cyclic amino acids and derivatives thereof useful as pharmaceutical agents

Amino acids with affinity for the &#x3b1;-2-delta-protein

This invention relates to novel cyclopropyl &#x3b2;-amino acids derivatives of the formulawherein Rthrough Rare defined as in the specification, pharmaceutical compositions containing them and their use for the treatment of various central nervous system and other disorders. The cyclopropyl &#x3b2;-amino acids derivatives of this invention exhibit activity as alpha2delta ligands (&#x3b1;2&#x3b4; ligands). Such compounds have affinity for the &#x3b1;2&#x3b4; subunit of a calcium channel.

Cycloproply &#x3b2;-amino acid derivatives

The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formulaand pharmaceutically acceptable salts thereof, wherein Ris hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases

Mono-and disubstituted 3-propyl gamma-aminobutyric acids

Growing community of inventors

Ann Arbor, MI, United States of America

David Juergen Wustrow